https://doi.org/10.1016/j.vaccine.2021.09.025.
 |
The schematic representation of the immunoinformatics guided design of the multi-epitope vaccine construct against K.pneumoniae. |
 |
| The structural arrangement of B and T-cell epitopes along with linkers and adjuvant for the final multi-epitope vaccine construct. |
 |
Secondary structure prediction of the final multi-epitope vaccine construct by using PSIPRED tool. |
 |
| Restriction cloning of final multi-epitope vaccine by using pET28a (+) expression vector in the in silico space. Black circle indicates the vector, and the magenta part is the place where the vaccine is inserted. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) |
 |
| Restriction cloning of final multi-epitope vaccine by using pET28a (+) expression vector in the in silico space. Black circle indicates the vector, and the magenta part is the place where the vaccine is inserted. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) |
 |
| Analysis of RMSD, and RMSF plots of native and mutant vaccine-TLR2 complex at 100 ns (a) Time evolution backbone RMSD plot of the native complex. (b) RMSF plot of the native structure. (c) RMSD plot of the mutant complex (d) RMSF plot of the mutant structure. |
 |
| Molecular interaction of multi-epitope vaccine construct docked with TLR2. |
 |
| The conformational B-lymphocyte epitopes present in the vaccine. The yellow spheres showing epitopes containing (a) 29 residues |
 |
| Disulphide engineering of the vaccine protein. Residue pairs showed in red (CYS107, VAL248) and green (CYS30, ALA201) spheres were mutated to Cysteine residues to form disulphide bridge between them. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) |
 |
| Several structure validation tools results confirmed the modeled multi-epitope vaccine structure to be reliable and accurate. |
 |
| Homology modeling of the three-dimensional structure of the final multiepitope vaccine construct. The green structure represents the epitopic protein antigen while the blue represents the adjuvant CTB (P01556) protein. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article. |
https://doi.org/10.3390/vaccines9080812
 |
The comparative illustration of traditional vaccine production and CoV vaccine development. The reasons for focusing on each of these technologies for COVID-19 include their rapid expansion, scale, and manufacturing fit, and small dose size, which are all highly desirable features for a rapid pandemic response. |
 |
| Computational approaches and online databases. The freely accessible integrated platforms can also be used as tools for coronavirus identification, analytical genomics evaluation, vaccine and drug discovery |
 |
| Types of Vaccine development approaches and platforms. They differ in whether they use the entire virus or bacterium, only the germs parts that activate the immune system or only the genetic material that instruction for making specific proteins rather than the entire virus. |
 |
Workflow employed for the vaccine design. |
 |
Schematic representation of the methodology for the development of multi-epitope vaccine against pneumonia fever. |
 |
| Developed multi-epitope vaccine structure validation results confirmed the model to be reliable and accurate. |
 |
| Developed multi-epitope vaccine structure validation results confirmed the model to be reliable and accurate. |
 |
| Secondary structure prediction of the final multi-epitope vaccine construct by using PSIPRED tool. |
 |
| The structural arrangement of B and T-cell epitopes along with linkers and adjuvant for the final multi-epitope vaccine construct |
 |
Molecular interaction between the predicted T-cell epitopes and their respective HLA binding alleles. |
